The Future of Medicine Starts Here
Nano24 is a clinical-stage company pioneering the next generation of immunomodulators; CD24-enriched exosomes, as a breakthrough therapy for hyperactivation of the immune system.
Founded in 2020, Nano24 Ltd. was established to commercialize cutting-edge technologies developed through years of applied and clinical research in Prof. Arber’s and Dr. Shapira’s lab.
Shaping the future of medicine requires simplicity, out-of-the-box thinking, and precision. At Nano24, we are committed to advancing science and technology, bringing together global experts and the latest discoveries to develop a powerful, innovative therapy for cytokine storm-related diseases.
It’s time to go beyond what’s been done before.
🚀 Nano24 is redefining the future of medicine! Join us in shaping the future!
Our EXO-CD24 technology was developed in the laboratory of Prof. Nadir Arber and Dr. Shiran Shapira, known pioneers in the field, based on over 20 years of academic research. The company’s executive team is composed of highly experienced professionals, each in their respective fields.
Dr. Kornowski brings more than 25 years of pharmaceutical industry experience. As Global Head of Partnering at Roche, she led around 70 deals a year. She later joined Gurnet Point Capital, the Bertarelli family's investment firm, and in 2021 became CEO of Boston Pharmaceuticals. There she advanced the company's lead asset from Phase IIa to Phase IIb and led its 2025 sale to GSK, a deal valued at up to $2 billion. At Nano24 she advises on strategy and fundraising.
Dr. Hashmi has about 30 years of global drug development experience across the US, Europe and Asia-Pacific, spanning small molecules, biologics and gene therapy. A veteran regulatory and CMC leader, he held senior roles at Alnylam, Biogen, where he established the company's offices in Japan and China, and Ziopharm. As Chief Regulatory & Technical Officer at Boston Pharmaceuticals, he built the company's regulatory and technical function and helped advance its lead program through Phase 2 to the GSK transaction. At Nano24 he advises on drug development and regulatory strategy.
Robert S. “Bob” Langer, ScD, is one of the world’s leading biomedical engineers and an Institute Professor at MIT, the Institute’s highest faculty rank. His pioneering work in biomaterials, controlled drug delivery, tissue engineering, and nanotechnology has enabled major advances in medicine, including sustained-release drug systems, vaccines, and regenerative-medicine technologies. He has co-founded numerous biotechnology companies, including Moderna, and his research has produced more than 1,300 granted or pending patents and over 1,500 publications. Dr. Langer is a member of the U.S. National Academies of Sciences, Engineering, and Medicine, and has received many of the field’s highest honors, including the National Medal of Science, the National Medal of Technology and Innovation, the Draper Prize, and the 2024 Kavli Prize in Nanoscience.
Prof. Arber is a Professor of medicine and gastroenterology. He is the Yechiel and Helen Lieber Professor for cancer research, serves as the Head of the Health Promotion Center and as the Head of the Integrated Cancer Prevention Center at the Tel-Aviv Sourasky Medical Center. Prof. Arber has extensive experience in clinical trials and technology development and vast network of clinical, scientific and commercial connections worldwide. In 1999, he became the head of the GI Oncology Unit at the Department of Gastroenterology at Tel Aviv Medical Center. In 2002, he established and led the Integrated Cancer Prevention Center (ICPC) at the Tel Aviv Medical Center. In 2010 he became the Director of the Cancer Research Center of Tel Aviv University, and since 2011 he heads the Djerassi-Ellias Oncology Center, both of them at Tel Aviv University. In 2014 he was chosen as the president elect of the Israeli Society of Gastroenterology and became the president in 2015 for a three-year term. Prof. Arber is a member of several international scientific committees at UEGF, ASNEMGE, ESMO-GO, GI-ASCO, OMED, and WGO. He published > 300 papers and received numerous grants and awards
Head of Research Laboratory Health Promotion Center and Integrated Cancer Prevention Center, a leading CD24 lab and R&D center of excellence compliant with OECD principles of GLP. Shapira's expertise includes molecular biology, antibody engineering, protein expression and purification, gene delivery, personalized medicine, animal models, and cell biology. Dr. Shapira has extensive experience in GMP pharmaceutical production and leads the manufacturing of EXO-CD24.
Head of the HIV Outpatient Clinic at the University of Bonn in Germany. Dr. Rockstroh is involved in HIV research on antiretroviral therapy, including new drug classes; Former president of the German AIDS Society. A member of the executive committee of the European AIDS Clinical Society (EACS). Member of the company’s SAB.
Head of the Cyclotron/Radiochemistry unit at Hadassah Hebrew University, Head of Research and Development Division, Hadassah Medical Center; Professor of Nuclear Medicine; Director, Cyclotron Radiochemistry Facility, Human Biology Research Center, Department of Nuclear Medicine. Member of the company’s SAB.
Dr. Schickler is Head of Clinical Operations at Purple Biotech and has extensive experience leading biopharmaceutical R&D, clinical development, manufacturing, and regulatory strategy.
has served as a director of Nano24 since 2023 and brings over 25 years of experience in venture capital industry, including his time spent serving on boards of directors of various companies and familiarity with Israeli companies. He has been with Gemini Israel Ventures, a venture capital fund, since January 1993 and Managing Partner since 1999 and the Chairman of Bridges Israel, an impact investment fund, since March 2018. Mr. Sela has served as a director of JFrog Ltd. (NASDAQ: FROG), an Israeli company traded on the NASDAQ since 2012. Mr. Sela currently serves on the board of directors of Technion R&D Foundation, a subsidiary of the Technion Israel Institute of Technology, as well as several privately held companies. He holds a B.Sc. in Electrical Engineering from the Technion - Israel Institute of Technology, Israel and an M.B.A. from the Tel Aviv University.
has extensive experience spanning over 25 years in the fields of medicine, healthcare management, and medical consulting. Since 2014, Dr. Ben-Ari has served as the Deputy Medical Director of the Jerusalem, Shfela, and North Districts at "Maccabi Health Care." Additionally, he acts as the Medical Director of Supplemental Medical Insurance Programs ("SHABAN") and provides advisory services for the Safety and Risk Management unit.
Seasoned entrepreneur and investment professional with a successful track record in founding, operating, and leading ventures in the real-estate, food and beverage, finance, and internet spaces. Currently actively investing in the areas of Cyber, Fin-tech, MedTech, and Prop-tech spaces. Ben is an active board member in several tech companies and managing director of Family Office.
Joseph D. Grant Professor And Professor Of Microbiology And IMMUNOLOGY and practices at Stanford Hospital and Clinics. In his Academic capacity, he is professor, Medicine - Gastroenterology & Hepatology, Professor, Microbiology & Immunology, Member Bio-X, Member, Maternal & Child Health Research Institute (MCHRI), Faculty Fellow, Stanford ChEM-H, Member, Wu Tsai Neurosciences Institute. Prof Glenn is also Director, Center for Hepatitis and Liver Tissue Engineering (2006 - Present).
Specializes in the treatment of lung and bronchial diseases in adults. Head of Department of interventional pulmonology.
Director of the Division of Surgery and Chair of the Department of Anesthesiology, Intensive Care and Pain at the Tel Aviv Medical Center, Israel. Chair of the Scientific Committee of the European Society of Anesthesiology (ESA). President of the Israeli Society of Anesthesiologists (ISA), representative for the ISA at the NASC and member of the nomination committee of the ESA. Dr Matot received her M.D at the Hebrew University, Jerusalem, Israel.
Mira has three decades of experience in scientific development as well as in building business strategies in the biotech industry. She Co-founded and led companies from the establishment to acquisitions in cancer immunotherapy.
Senior Product specialist Cell Biology Drug Discovery, ADME/Tox, Stem & Primary Cells, Cell Therapy. Tim has vast experience in the pharmaceuticals industry from the supplier side and with regards to the development of new therapies. Currently, Tim is part of the division on Thermo-Fisher that provides the company with cell line for product development. Tim consults the company with regards to manufacturing, MCB, tech transfer, and manufacturing upscale aspects.
Bilic (Billy) Hrvoye is the co-founder and CEO of Annapurna Labs (Amazon company). Annapurna is part of AWS (Amazon Web Service) cloud. Annapurna was co-founded in 2011 with Nafea Bshara, Avigdor Wilentz and Ronen Boneh, with the dream to create the world's most innovative semiconductor company. In 2015 Annapurna Labs got acquired by Amazon/AWS and became the team in charge of all AWS (Amazon Web Service) semiconductor development World Wide.